DE69927689D1 - Lipid-senkende chinazoline derivate - Google Patents

Lipid-senkende chinazoline derivate

Info

Publication number
DE69927689D1
DE69927689D1 DE69927689T DE69927689T DE69927689D1 DE 69927689 D1 DE69927689 D1 DE 69927689D1 DE 69927689 T DE69927689 T DE 69927689T DE 69927689 T DE69927689 T DE 69927689T DE 69927689 D1 DE69927689 D1 DE 69927689D1
Authority
DE
Germany
Prior art keywords
lipid
reducing
chinazoline derivatives
cholesterol
chinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927689T
Other languages
English (en)
Other versions
DE69927689T2 (de
Inventor
M Uckun
N Trieu
Xing-Ping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Application granted granted Critical
Publication of DE69927689D1 publication Critical patent/DE69927689D1/de
Publication of DE69927689T2 publication Critical patent/DE69927689T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69927689T 1998-07-30 1999-07-13 Lipid-senkende chinazoline derivate Expired - Fee Related DE69927689T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US126940 1993-09-24
US09/126,940 US6172071B1 (en) 1998-07-30 1998-07-30 Lipid-lowering quinazoline derivative
PCT/US1999/015841 WO2000006554A1 (en) 1998-07-30 1999-07-13 Lipid-lowering quinazoline derivative

Publications (2)

Publication Number Publication Date
DE69927689D1 true DE69927689D1 (de) 2006-02-23
DE69927689T2 DE69927689T2 (de) 2006-07-20

Family

ID=22427479

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927689T Expired - Fee Related DE69927689T2 (de) 1998-07-30 1999-07-13 Lipid-senkende chinazoline derivate

Country Status (13)

Country Link
US (2) US6172071B1 (de)
EP (1) EP1100787B1 (de)
JP (1) JP2002521475A (de)
KR (1) KR20010089146A (de)
AT (1) ATE306476T1 (de)
AU (1) AU750653B2 (de)
CA (1) CA2338825A1 (de)
DE (1) DE69927689T2 (de)
HU (1) HUP0102887A2 (de)
IL (1) IL141025A0 (de)
MX (1) MXPA01001139A (de)
NO (1) NO20010525L (de)
WO (1) WO2000006554A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6410545B2 (en) 1998-07-30 2002-06-25 Parker Hughes Institute Lipid lowering quinazoline dietary supplement composition
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
UA81619C2 (ru) 2002-02-01 2008-01-25 Астразенека Аб Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
RU2448977C2 (ru) * 2004-09-16 2012-04-27 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
AU2005314043A1 (en) * 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN104016929B (zh) * 2014-06-25 2016-03-30 北京理工大学 一种合成喹唑啉-4(3h)-酮的方法
DK3416684T3 (da) * 2016-02-17 2023-07-31 Regeneron Pharma Fremgangsmåder til behandling eller forebyggelse af atherosklerose ved administration af en hæmmer af ANGPTL3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative

Also Published As

Publication number Publication date
US6355645B2 (en) 2002-03-12
JP2002521475A (ja) 2002-07-16
NO20010525D0 (no) 2001-01-30
EP1100787A1 (de) 2001-05-23
AU4991399A (en) 2000-02-21
NO20010525L (no) 2001-01-30
US20010008894A1 (en) 2001-07-19
IL141025A0 (en) 2002-02-10
CA2338825A1 (en) 2000-02-10
EP1100787B1 (de) 2005-10-12
US6172071B1 (en) 2001-01-09
HUP0102887A2 (hu) 2003-02-28
DE69927689T2 (de) 2006-07-20
KR20010089146A (ko) 2001-09-29
WO2000006554A1 (en) 2000-02-10
ATE306476T1 (de) 2005-10-15
AU750653B2 (en) 2002-07-25
MXPA01001139A (es) 2002-04-24

Similar Documents

Publication Publication Date Title
DE69927689D1 (de) Lipid-senkende chinazoline derivate
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
EP1450808B8 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
EP1707563A3 (de) Chinazolinone Benutzende Verfahren und Zusammenstellungen
WO2003042172A3 (en) C-5 modified indazolylpyrrolotriazines
NO20005864L (no) Kinazoliner til behandling av hjernesvulst
CY1110511T1 (el) Διαδικασια για την παρασκευη της 4-(3'-χλωρο-4'-φθοροανιλινο)-7-μεθοξυ-6-(3-μορφολινοπροποξυ)κουιναζολινης
DE69806696T2 (de) N,N',N''-Tris(2,4-Bis(1-Hydrocarbyloxy-2,2,6,6-tetramethylpiperidin-4-yl)alkylamino)-s-triazin-6-yl)-3,3'-ethylenediiminodipropylamine, ihre Isomere und überbrückte Derivate, sowie damit stabilisierte Polymerzusammensetzungen
MY131890A (en) Piperidine compounds
WO2002032893A3 (en) Piperidine compounds as anti-allergic
WO2001012606A3 (en) Tetrahydroquinoline derivatives having retinoid-like biological activity
EP1686120A3 (de) Chinazolinone benutzende Verfahren und Zusammenstellungen
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
DE60137966D1 (de) Anilinopyrimidin derivate als "jnk pathway inhibitoren", zusammensetzungen und damit verbundene behandlungsmethoden
WO2004054514A3 (en) C-6 modified indazolylpyrrolotriazines
ATE232865T1 (de) 1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
DE60204349D1 (de) 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung
ATE259357T1 (de) Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE69613705D1 (de) Piperinderivate als neurokininantagoniste
DE60001307D1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
CA2330447A1 (en) N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
DE60103394D1 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
DE60206171D1 (de) Kaliumkanal-modulierende imidazolderivate
DE69909577D1 (de) Derivate von Erythromycin, ihr Verfahren zur Herstellung, und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee